Medical Device Go-to-Market: Why Most Launches Stall Before They Scale

A medical device go-to-market strategy is the structured plan that takes a device from regulatory clearance to commercial revenue, covering market selection, channel design, clinical positioning, pricing, and the sequence in which you build each. Most launches that stall do so not because the product fails, but because the commercial infrastructure was never built to match the complexity of the buying environment.

Medical devices sit at the intersection of clinical evidence, procurement politics, and economic justification. That combination makes the go-to-market problem harder than most categories, and it makes generic launch frameworks almost useless.

I have worked across more than 30 industries over two decades in agency leadership, and the medical device category is one of the few where I consistently see sophisticated companies making the same structural mistakes in their commercial planning. Not because they lack smart people, but because the GTM problem is genuinely hard and the feedback loops are slow. A hospital sale can take 12 to 18 months. By the time you know your approach is broken, you have already burned through a significant portion of your launch budget.

If you are thinking about go-to-market strategy more broadly, the Go-To-Market & Growth Strategy hub covers the commercial frameworks that sit underneath category-specific execution like this one.

Who Actually Buys a Medical Device?

This sounds like an obvious question. It is not. In most consumer categories, the buyer and the user are the same person. In medical devices, you are almost always dealing with a committee, and each member of that committee has a different motivation and a different veto point.

The clinical user, typically a surgeon, interventionalist, or specialist nurse, cares about outcomes, ease of use, and how the device compares to what they already know. The economic buyer, usually a VP of supply chain, a CFO, or a materials management director, cares about unit cost, contract terms, and whether the device fits within an existing GPO agreement. The administrative layer, including compliance, legal, and biomedical engineering, cares about regulatory status, service agreements, and liability exposure.

Getting clinical buy-in without economic buy-in gets you a champion with no budget. Getting economic buy-in without clinical buy-in gets you a contract that nobody uses. I have seen both happen more than once, and both are expensive failures.

Your GTM strategy has to be built around this multi-stakeholder reality from the beginning, not retrofitted once you discover the clinical champion cannot get the device on formulary.

Market Segmentation: Which Segments Are Actually Accessible at Launch?

Most device companies segment by specialty and geography. That is a reasonable starting point, but it misses the commercial variables that actually determine whether a segment is winnable in year one.

Reimbursement coverage is the first filter. If a procedure does not have a well-established reimbursement pathway, the economic buyer has no mechanism to justify the cost, regardless of clinical merit. This is not a marketing problem. It is a market access problem, and it needs to be resolved before you invest heavily in commercial activity in that segment.

IDN structure matters enormously. A large integrated delivery network with a centralized formulary committee is a very different sales environment from a community hospital with a single medical director making purchasing decisions. The former requires a top-down enterprise sale with clinical and economic evidence aligned. The latter can often be moved by a strong clinical relationship and a compelling demonstration.

GPO relationships shape which accounts are even accessible at your current price point. If your target accounts are locked into GPO contracts with a competitor, you are not selling against the competitor’s product. You are selling against the sunk cost of a contract renewal that is 18 months away.

The segments worth prioritising at launch are those where reimbursement is established, IDN structure allows for decentralised purchasing decisions, and your clinical evidence is strong enough to justify a formulary addition. That is a narrower beachhead than most commercial teams want to accept. It is also the one that actually generates early revenue and reference accounts.

Before you finalise your segment priorities, a structured audit of your current commercial position is worth the time. The checklist for analysing company website for sales and marketing strategy is a useful starting point for identifying where your digital presence is misaligned with your actual buyer experience.

Clinical Evidence as a Commercial Asset, Not Just a Regulatory Requirement

I spent time working with clients in highly regulated categories where the instinct was to treat clinical evidence purely as a compliance function. The regulatory team owns it, the medical affairs team publishes it, and the commercial team points to it vaguely in sales decks. That is a significant missed opportunity.

Clinical evidence is your most powerful commercial asset, particularly with economic buyers. A health economics and outcomes research case, showing reduced procedure time, shorter length of stay, or lower complication rates, translates clinical performance into financial terms that a CFO or supply chain director can act on. Without that translation, you are asking economic buyers to take a clinical leap of faith, and most of them will not.

The companies that build clinical evidence programs with commercial intent, not just regulatory intent, consistently outperform those that treat them as separate functions. This means working backwards from the questions economic buyers actually ask: What does this cost per procedure compared to the alternative? What is the readmission rate? What is the impact on OR throughput? The answers to those questions need to be in your evidence base before you start selling into large systems.

Peer-reviewed publication matters too, but not for the reason most companies assume. It is not primarily about credibility with clinicians who have already seen a demonstration. It is about giving your clinical champions the ammunition they need to make the case internally, to a committee that has not seen the device and is making a decision based on paper.

Channel Design: Where Most Device GTM Strategies Break Down

The default channel model for medical devices is a direct sales force supported by clinical specialists, with distributor coverage in geographies where direct sales are not economical. That model works, but it is expensive, slow to build, and carries significant fixed cost before you have proven commercial traction.

The honest question at launch is whether you have the capital and the timeline to build a direct sales infrastructure, or whether you need to generate revenue faster than that infrastructure can be built. Those are two very different strategic situations, and they require different channel decisions.

If capital is constrained, a distributor-first model in your beachhead segments can generate early revenue and reference accounts while you build the direct team. The trade-off is margin and control. Distributors will not carry your message with the same precision as a trained direct rep, and they will not prioritise your product when they have an easier sale in their bag. Managing that tension requires tight distributor selection, strong training programs, and clear performance expectations from the beginning.

For companies with longer sales cycles and complex clinical selling environments, pay per appointment lead generation models can be a useful mechanism for generating qualified introductions to clinical decision-makers, particularly in specialties where cold outreach has low conversion rates.

Digital channels are increasingly relevant in medical device GTM, particularly for reaching clinicians in the research phase of their decision process. But digital alone will not close a hospital sale. It can build awareness, generate inbound interest, and support the clinical champion’s internal case-making. It cannot replace the in-person demonstration, the clinical evaluation period, or the economic justification conversation with the CFO.

One channel that is consistently underused in medical device marketing is endemic advertising in specialty clinical publications and digital properties. Clinicians do not respond to generic display advertising, but contextually relevant placements in the journals and platforms they already use for clinical education can build meaningful awareness at a fraction of the cost of conference sponsorship.

Pricing Strategy: The Variable Most GTM Plans Underspecify

Pricing in medical devices is not just a financial decision. It is a positioning decision, a reimbursement decision, and a competitive signal all at once. Getting it wrong at launch is very difficult to recover from, because price anchoring in institutional procurement is sticky. Once you are in a GPO contract at a certain price point, renegotiating upward is nearly impossible.

The pricing framework needs to account for four things simultaneously: the cost-effectiveness threshold that economic buyers will accept, the reimbursement rate that defines the ceiling for what hospitals can afford to pay, the competitive price point that defines the floor for clinical credibility, and the margin structure that makes your business commercially viable.

Those four variables do not always point to the same number. When they do not, you have a market access problem that pricing alone cannot solve. BCG has written extensively on pricing strategy in B2B go-to-market contexts, and the principle that pricing strategy needs to be built into GTM design rather than bolted on afterwards applies with particular force in medical devices.

Value-based pricing, where the price is anchored to clinical and economic outcomes rather than to cost-plus or competitive benchmarking, is the right framework for most novel devices. But it requires the evidence infrastructure discussed earlier. You cannot charge a premium for outcomes you have not demonstrated.

The Demand Creation Problem in Medical Devices

Earlier in my career I was heavily focused on lower-funnel performance. Capture the intent, convert the lead, attribute the sale. It took me longer than I would like to admit to recognise that most of what performance marketing takes credit for was going to happen anyway. The surgeon who searches for your device category has already formed an opinion. The hospital procurement team that downloads your white paper has already been briefed by a rep. You are capturing demand that was created somewhere else, and calling it marketing.

Real demand creation in medical devices means reaching clinicians before they have a defined need. It means building awareness of a clinical problem and positioning your device as part of the solution before the procurement process begins. That requires investment in channels and content that do not have clean attribution, which makes them uncomfortable for commercially-minded leadership teams who want to see cost-per-lead metrics.

The companies that build durable market positions in medical devices invest in clinical education, peer networks, society relationships, and thought leadership that operates well above the purchase funnel. Go-to-market is getting harder across most B2B categories because buyers are more informed and more sceptical. In medical devices, that dynamic is amplified by the clinical stakes involved.

Key opinion leader programs, when run with genuine clinical intent rather than as thinly veiled promotional activity, are one of the most effective demand creation mechanisms available to device companies. A respected surgeon presenting real-world outcomes at a society conference does more for awareness and credibility than any amount of conference booth space.

Digital Marketing in a Regulated Environment

Medical device marketing operates under FDA promotional regulations, and those constraints shape what you can say, where you can say it, and how claims need to be substantiated. This is not a reason to avoid digital marketing. It is a reason to build a digital strategy that is designed around compliance from the beginning, rather than having legal review strip out the most effective parts of your content after the fact.

The most effective digital programs I have seen in regulated healthcare categories are built around education rather than promotion. Content that helps clinicians understand a clinical problem, interpret evidence, or improve their practice generates trust and engagement that promotional content simply cannot. It also tends to survive regulatory review intact, because it is making clinical claims that are supported by published evidence rather than marketing claims that require substantiation.

SEO is a legitimate channel for medical device companies targeting clinicians in the research phase of their decision process. A clinician searching for comparative outcomes data on a device category is a high-value audience, and content that answers those questions with clinical rigour will rank and convert. Market penetration through organic search takes longer to build than paid channels, but the audience quality is often higher and the cost per engagement is lower at scale.

Before building out your digital strategy, a thorough review of your current digital position is worth doing. Digital marketing due diligence covers the analytical framework for assessing where your current investment is working and where it is not, which is particularly important in medical devices where the feedback loops between marketing activity and commercial outcome are slow.

The Structural Difference Between a Startup Device Launch and an Established Company Line Extension

These are two fundamentally different GTM problems, and they are often treated as if they were the same.

A startup launching its first device has no installed base, no reference accounts, no sales infrastructure, and no brand recognition in the clinical community. The GTM problem is almost entirely about proving clinical and commercial viability in a defined beachhead, generating the reference accounts and evidence that make the next sale easier, and building the commercial infrastructure in parallel with early revenue generation. Speed matters, but not at the expense of the quality of early implementations. A bad early case study in a clinical setting can damage a device’s reputation in ways that are very hard to recover from.

An established company launching a line extension has a different set of advantages and a different set of risks. The sales infrastructure exists. The clinical relationships exist. The GPO contracts exist. The risk is that the existing commercial organisation defaults to selling the new product the same way it sells the existing portfolio, which may not be appropriate if the new product addresses a different clinical indication, a different buyer, or a different care setting.

The corporate and business unit tension is real here. A corporate and business unit marketing framework that clarifies which decisions sit at the brand level and which sit at the product level can prevent the kind of organisational confusion that slows launch execution in larger companies.

I have managed marketing for businesses going through exactly this tension, where the parent brand had strong equity but the new product needed to establish its own clinical identity. Getting that balance wrong in either direction, either hiding the new product under the corporate brand or positioning it so independently that it loses the halo of the parent’s credibility, is a common and costly mistake.

What Medical Device GTM Can Learn From Other Complex B2B Categories

Medical devices are not the only category with long sales cycles, multiple stakeholders, regulatory constraints, and high switching costs. Financial services, enterprise software, and industrial equipment share many of the same commercial dynamics, and there is useful cross-pollination available if you are willing to look outside the category.

B2B financial services marketing has developed sophisticated frameworks for managing multi-stakeholder buying processes, building trust in regulated environments, and using content to move buyers through long consideration cycles. The parallels to medical device GTM are closer than most device marketers recognise.

BCG’s work on go-to-market strategy in financial services addresses the challenge of aligning sales and marketing in environments where the buying process is long, the buyer is sophisticated, and the product is complex. The core principles apply directly to medical devices: segment by accessibility not just by size, align clinical and economic messaging to different buyer types, and build the evidence infrastructure that supports the economic case.

The Forrester intelligent growth model is another framework worth understanding, particularly its emphasis on building growth through customer experience and retention rather than purely through acquisition. In medical devices, where a device that genuinely improves clinical outcomes will generate repeat purchases, referrals, and clinical advocacy, the customer experience after the sale is as commercially important as the sale itself.

I have seen this play out in practice. Companies that invest in clinical support, training, and outcomes tracking after the sale generate the reference accounts and KOL relationships that make the next sale significantly easier. Companies that treat post-sale as a service cost rather than a commercial investment tend to plateau once the initial addressable market is penetrated.

Measurement: What Good Looks Like in a Long Sales Cycle

Medical device GTM measurement is genuinely hard. The sales cycle is long, the attribution is complex, and the marketing activities that matter most, clinical education, KOL relationships, society presence, are the ones that are hardest to measure with precision.

The answer is not to abandon measurement. It is to build a measurement framework that distinguishes between leading indicators and lagging indicators, and that is honest about the limits of attribution in a long-cycle environment.

Leading indicators worth tracking include clinical awareness metrics from periodic surveys of target specialists, pipeline velocity by segment, number of active clinical evaluations, and engagement rates with clinical education content. These give you a read on whether your commercial activity is building the conditions for future sales, even when those sales have not closed yet.

Lagging indicators are the commercial outcomes: revenue by segment, market share in target accounts, average selling price relative to target, and customer retention rates. These tell you whether the strategy is working, but they tell you slowly. If you wait for lagging indicators to confirm a problem, you have already lost 12 months of launch momentum.

Marketing analytics tools give you a perspective on reality, not reality itself. A clinician who engages with your content three times before a rep call does not show up in your CRM as a marketing-influenced opportunity unless someone builds that connection deliberately. The measurement infrastructure needs to be designed alongside the GTM strategy, not added afterwards.

If you want to go deeper on the broader commercial frameworks that underpin effective medical device launches, the Go-To-Market & Growth Strategy hub covers the strategic architecture that sits above category-specific execution, including how to sequence market entry, build commercial infrastructure, and align marketing with revenue outcomes.

About the Author

Keith Lacy is a marketing strategist and former agency CEO with 20+ years of experience across agency leadership, performance marketing, and commercial strategy. He writes The Marketing Juice to cut through the noise and share what works.

Frequently Asked Questions